Clinic outcome evaluation of tamsulosin therapy for benign prostatic hyperplasia

ABSTRACT

To evaluate the clinical outcome of the once daily oral dose of tamsulosin [0.4 mg] for managing clinical benign prostatic hyperplasia [BPH], a total of 157 out of 186 patients completed the 6-month follow up study protocol. All cases had a bothersome international prostate symptom score [IPSS] of more than 7 and peak flow rate [PFR] of less than 12 ml/second with no absolute surgical indications. The efficacy assessment variables included monitoring IPSS, peak flow rate [PFR] and post-voiding residual volume [PVR] for six months through five outpatients clinic visits [initial, two weeks, six weeks, three months and six months]. The clinical outcome was satisfactory in 124/157 patients with documented improved IPSS and/or PFR. An unsatisfactory outcome occurred in 33/157 patients; 19 showed no improved IPSS and/or PFR, 11 were unsatisfied and decided to undergo surgery and 3 developed acute urinary retention which was persistent and required to undergo surgery. Adverse effects occurred in 21/157 patients including dizziness in 6/157 patients, asthenia in 8/157, abnormal ejaculation in 11/157, rhinitis in 4/157 and severe adverse effects necessitating drug withdrawal in 3/157 patients